Signatope
Private Company
Funding information not available
Overview
Signatope is a fast-growing, privately-held German biotech providing innovative proteomics services for the pharmaceutical and diagnostics sectors. Its proprietary platform, based on antibodies targeting minimal 4-amino-acid epitopes, allows for the development of highly specific, cross-species quantitative assays for challenging protein biomarkers, including isoforms and drug transporters. The company primarily serves drug development pipelines by offering critical tools for safety and toxicology biomarker assessment, positioning itself at the intersection of advanced proteomics and preclinical/clinical research support. Recent recognition, such as the Deloitte Technology Fast 50 Award, underscores its rapid growth and technological validation.
Technology Platform
Proprietary immunoassay platform using antibodies that target ultra-short, 4-amino-acid epitopes, enabling quantitative, cross-species, and isoform-specific protein detection.
Opportunities
Risk Factors
Competitive Landscape
Signatope competes with large antibody/assay vendors (e.g., Thermo Fisher, Abcam), specialized contract research organizations (CROs) offering biomarker services, and academic/core labs using LC-MS/MS proteomics. Its differentiation lies in the unique cross-species capability and specificity for difficult targets offered by its short-epitope technology.